Skip to main content

Table 2 Characteristics at inclusion and after rituximab

From: Rituximab for auto-immune alveolar proteinosis, a real life cohort study

Mean values

At Rituximab injection

After rituximab

p-value*

M3

M6

M12

Number of patients

13

11

11

11

 

D(A-a)O2 (mmHg)

40 (31–57)

43 (34–60)

40 (31–56)

35.9 (15–60)

0.19

PaO2 (mmHg)

68 (57–82)

63 (55–70)

65 (52–78)

70 (49–92)

0.51

Disease Severity Score

2.7 (2–4)

3.0 (2–4)

2.8 (2–4)

2.3 (1–5)

0.44

VC (%predicted value)

79 (36–100)

78 (61–87)

79 (50–100)

84 (62–102)

0.81

DLCO (% predicted value)

54 (19–92)

46 (30–86)

50 (29–79)

63 (35–97)

0.38

Serum anti-GM-CSF

 ELISA (μg/mL)/Available

99 (18–220)/8

Na

85 (19–187)/7

7.7 (3.1–158)/6

0.19

 Functional (titer)/Available

853 (200–4000)/9

Na

831 (30–4000)/11

436 (0–1400)/8

0.21

CT-grade

19.3 (12–28)

Na

19.3 (13–28)

17.3 (6–26)

0.73

  1. *between at rituximab injection and M12, VC Vital capacity, DLCO Diffusing capacity of the lung for carbon monoxide, CT Computed tomography, D(A-a)O 2 alveolar–arterial gradient at rest, na not available